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Core binding factor acute myeloid leukemia (CBF-AML), characterized by the chromosomal abnormalities of t(8;21) (AML1-ETO) or inv(16)/t(16;16) (CBFB-MYH11), is the most frequent subtype in pediatric AML. Although CBF-AML is generally classified as a low-risk group, in a recent analysis of 154 patients with CBF-AML participating in the Japanese Pediatric Leukemia/ Lymphoma Study Group (JPLSG) AML-05 trial (2006) (2007) (2008) (2009) (2010) , 29.9% of the patients relapsed within 3 years. 1 This finding suggests that a population of the CBF-AML patients had other risk factors that could account for their poor outcome. The KIT gene, located on chromosome 4, encodes a type III receptor tyrosine kinase activated by stem cell factor (SCF), and leads to cell survival, migration and proliferation. 2 In adults with CBF-AML, gain-offunction mutations of KIT are risk factors. [3] [4] [5] [6] [7] These mutations cluster in exon 8 (encoding the extracellular domain of KIT), exon 17 (encoding the activation loop of the tyrosine kinase domain) and occasionally in exon 10 or 11 (encoding the transmembrane domain and the juxtamembrane domain, respectively). Among these mutations, KIT exon 17 D816 mutations have been shown to confer a poor prognosis to adult patients with t(8;21). 3, 4, 7 In pediatric CBF-AML, some studies [8] [9] [10] found no clinical impact of KIT mutations, whereas Shimada et al. 11 and Manara et al. 12 studying the prognostic impact of KIT mutations in pediatric t(8;21) AML both concluded that KIT mutations may be poor prognostic factors ( Supplementary Table S1 ). These retrospective studies, however, could be influenced by selection bias of the cytogenetic subtype. Therefore, a further validation study that includes all of the targeted cytogenetic subtypes (t(8;21) and inv (16)/t(16;16)) and KIT mutations in a larger cohort is necessary to elucidate any involvement of KIT mutations in the prognosis of pediatric CBF-AML.
In this study, we analyzed KIT mutations in 138 pediatric CBF-AML patients participating in the JPLSG AML-05 trial whose complementary DNA (cDNA) from their diagnostic bone marrow samples were available; 107 patients carried a t(8;21) rearrangement and 31 an inv (16) . KIT mutations in exons 8, 10, 11 and 17 were screened using direct sequencing of cDNA. 11 Event-free survival (EFS) was measured from the time of diagnosis to the last follow-up or the first event (failure to achieve remission, relapse, secondary malignancy or death), and overall survival (OS) was measured from the time of diagnosis to death. The 3-year probability of EFS (pEFS) and the 3-year probability of OS (pOS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Differences between cumulative incidence of relapse (CIR) curves were compared using Gray's test. Statistical analyses were performed with STATA software (version 13.0; StataCorp LP, College Station, TX, USA) and R software (version 3.0.2, The R Foundation for Statistical Computing, Vienna, Austria).
KIT mutations were found in 46/107 (43.0%) t(8;21) and 12/31 (38.7%) inv(16) patients ( Table 1 ). Of the 46 t(8;21) patients, exon 8 mutations were detected in 8 (17.4%), exons 10 and/or 11 mutations in 10 (21.7%), exon 17 mutations in 23 (50.0%), both exons 8 and 10 mutations in 3 (6.5%), both exons 8 and 17 mutations in 1 (2.2%), and both exons 10 and 17 mutations in 1 (2.2%) patients. Of the 12 inv(16) patients, six (50.0%) had mutations in exon 8, one (8.3%) had mutations in exon 10, four (33.3%) had mutations in exon 17 and one (8.3%) had mutations in both exons 8 and 17. Exon 8 mutations were in-frame deletions and/or insertions of fewer than 13 bases around codon 418. Exon 10 mutations were either M541L or V540L. Exon 11 mutations were either V560D or a 45-base pair internal tandem duplication (ITD). Exon 17 had D816 point mutations (D816V, D816H or Accepted article preview online 15 May 2015; advance online publication, 9 June 2015 Abbreviations: CBF-AML, core binding factor acute myeloid leukemia; CI, confidence interval; CIR, cumulative incidence of relapse; CR, complete remission; ex, exon; pEFS, probability of event-free survival; pOS, probability of overall survival; WT, wild-type. a Multiple comparisons between ex 8, 10 and/or 11, 17, D816Y), D820 point mutations (D820G or D820V), N822K or R815_D816insL. No significant difference was observed in sex, age and white blood cell count at diagnosis between CBF-AML patients with or without KIT mutations (P = 0.828, 0.912 and 0.673, respectively; Supplementary Table S2 ). FLT3/ITD was found in 1 of the 58 CBF-AML patients with KIT mutations and in 4 of the 80 without KIT mutations, and this frequency did not differ significantly between the groups (P = 0.398). Complete remission rates were also similar in both groups (93.1 and 95.0% in patients with and without KIT mutations, respectively, P = 0.573; Table 1 ). The EFS rate and the CIR were significantly less favorable in CBF-AML patients with KIT mutations than in those without (3-year pEFS: 58% vs 75%, P = 0.029 and 3-year CIR: 38% vs 20%, P = 0.024, respectively), and were comparable to those of the intermediate-risk group (Table 1, and Figures 1a and c) . In the analysis stratified according to locations of the KIT mutation, the patients with exon 8 and those with exon 17 mutations had a higher CIR than those without KIT mutations, although these differences lost significance after applying the Bonferroni correction (exon 8 vs wild type (WT): P = 0.015, Bonferroni-adjusted P = 0.060 and exon 17 vs WT: P = 0.040, Bonferroni-adjusted P = 0.160). On the other hand, OS rates associated with the presence of KIT mutations or location of the mutation were indistinguishable (Table 1, Figure 1b ).
Next we studied the prognostic influence of KIT mutations stratified by t(8;21) and inv (16) independently. The t(8;21) patients with KIT mutations had a significantly lower EFS (3-year pEFS: 56% with KIT mutations vs 75% with WT KIT, P = 0.037; Table 1 ). Moreover, the 3-year pEFS according to the location of the KIT mutation was markedly different (38%, 80%, 49%, 80% and 75% for exon 8, exon 10 and/or 11, exon 17, mutations in 41 location, and WT, respectively; P = 0.041), and exon 17 mutations reached statistical significance compared with WT (P = 0.012, Bonferroniadjusted P = 0.048), whereas exon 8 mutations did not (P = 0.032, Bonferroni-adjusted P = 0.128). Furthermore, the higher CIR curves were observed in the patients with exon 8 or 17 mutations, although the differences did not reach significance (exon 8 vs WT: P = 0.014, Bonferroni-adjusted P = 0.056 and exon 17 vs WT: P = 0.032, Bonferroni-adjusted P = 0.128; Table 1 ). Fourteen (13.1%) of the 107 t(8;21) patients had D816 mutations (eight with D816V, three with D816H, one with D816Y, one with D816V+D816Y and one with R815_D816insL), and the EFS and OS rates, along with the CIR of these patients, were significantly less favorable than for the other t(8;21) patients without D816 mutations (3-year pEFS: 34 vs 72%, P o 0.001; 3-year pOS: 69 vs 96%, P = 0.001; and 3-year CIR: 59 vs 26%, P = 0.007, respectively; Table 1 ). On the other hand, we did not find any significant association of KIT mutations with the outcome of inv(16) patients (Table 1) .
Our findings suggest that KIT mutation is a poor prognostic factor in pediatric CBF-AML. Most of the relapsed patients in the AML-05 trial were salvaged by allogeneic hematopoietic stem cell transplantation (HSCT), which could be a primary reason for the indistinguishable OS between the patients with and without KIT mutations. Our results are also consistent with previous pediatric studies reported by Shimada et al. 11 and Manara et al. 12 , and with reports on adult patients. [3] [4] [5] [6] [7] Our study involved a relatively large cohort of pediatric CBF-AML patients and comprised all kinds of major KIT mutations, and thus the likelihood of demonstrating any adverse impact of KIT mutations was therefore high. Intriguingly, the 3-year CIR of CBF-AML patients in the AML-05 study was significantly higher than in the previous AML99 study 1 and was coincident with a higher frequency of KIT mutations. Although it may have been partially owing to changes in therapeutic regimens, this result suggests that the higher incidence of KIT mutations in the AML-05 study led to the increased relapse rate. This study was limited to Japanese CBF-AML patients, and therefore the question remains whether the results may have been influenced by ethnicity, treatment regimens and experimental methods. These factors may contribute the difference between this study and the largest study reported by Pollard et al. 10 , which found no clinical impact of KIT mutations. A large international study is expected to answer this. Among the KIT mutations, exon 17 mutations showed a marked adverse impact on patients with t(8;21). In particular, exon 17 D816 mutations resulted in a much poorer outcome, suggesting that this region in the activation loop domain of KIT has the greatest prognostic impact among all the KIT mutations. Gain-offunction mutations in this region are known to cause SCFindependent activation of KIT, which triggers its downstream signaling, activating cellular proliferation. 2 In an AML mouse model, co-expression of AML1-ETO with a mutated KIT activation loop domain induces a more aggressive AML phenotype than coexpression with a mutated KIT extracellular domain. 13 These findings further support the possibility that alterations in the signaling pathway due to D816 mutations have a critical role in leukemogenesis, linking the presence of D816 mutations with poor prognosis.
Our findings, along with those of others, indicate that KIT mutations should be regarded as stratification factors in pediatric CBF-AML, especially exon 17 mutations in t(8;21), and improvement of standard chemotherapy regimens 14 and additional specific therapies would be required for patients with KIT mutations. For example, the tyrosine kinase inhibitor (TKI) dasatinib has been shown to be active against cells coexpressing KIT N822K and AML1-ETO in a murine AML model and in Kasumi-1 cells, and against cells expressing KIT D816V in vitro. 15, 16 Combination therapies of dasatinib with conventional chemotherapy in adult CBF-AML are currently being tested in phase-I/II studies (NCT01238211 and NCT00850382). For CBF-AML patients with KIT abnormalities, KIT-targeting therapies, including TKIs, are expected to reduce the risk of relapse and subsequent need for HSCT.
